Refine by
Natural Killer Cells For Derived Allogeneic Therapies Equipment & Supplies
22 equipment items found
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
The next generation CORE-NK platform will integrate additional activation and expansion features to further optimize the cancer-fighting power of the CORE-NK platform cells. Development of the next generation CORE-NK platform will be as a combination therapy for blood ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 3301 (Undisclosed CAR NK) will be developed on the next generation CORE-NK platform leveraging a currently undisclosed Chimeric Antigen ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 2301 (CDH17 CAR NK) will be developed on the next generation CORE-NK platform leveraging our CDH17 Chimeric Antigen ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 1301 (CLTX CAR NK) will be developed on the next generation CORE-NK platform leveraging our CLTX Chimeric Antigen ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
The CORE-NK platform is a transformative platform technology for Chimeric enabling the accelerated development of multiple next generation, off the shelf NK and CAR-NK products. Natural killer cells are found in our bodies naturally and are able to recognize and kill cancer cells – but are not robust and active enough to overcome cancer as it grows. CORE-NK platform cells are made by ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
Pursuing an Unmet Need in the Treatment of CRC - SENTI-401 is designed to more precisely target and eliminate colorectal cancer (CRC) cells while sparing healthy cells elsewhere in the body. Our vision is a potential medicine that more effectively treats patients with colorectal ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity. ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK00X: Kiadis is evaluating preclinical programs with K-NK-cell therapies for the treatment of hematologic and solid ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
Pursuing an Unmet Need in the Treatment of AML - SENTI-202 is designed to target and eliminate acute myeloid leukemia cells while sparing healthy bone marrow. Our vision is a potential medicine that does not rely on an invasive bone marrow ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
Our lead clinical stage natural killer (NK) cell therapy, is an autologous platform technology that activates NK cells to kill cancers expressing a unique membrane form of Heat Shock Protein 70 ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
An autologous mHsp70 targeted NK Cell Therapy that activates NK cells to target and kill cells expressing mHsp70. The therapy begins with selecting patients whom have high mHsp70 expression with our Companion Diagnostic AP-CDx (described below), collecting their peripheral blood mononuclear cells (PBMCs) by leukapheresis, ex vivo activation of PBMCs with our synthetic Hsp70-derived peptide ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
Natural Killer (NK) cells are essential components of the immune system, playing an important role in the body’s defensive response against tumors and infected cells. NK cells constantly patrol the body to detect and neutralize foreign cells. Senti Bio believes there are several advantages that NK cells confer in relation to other potential immune cell types in oncology: innate killing, ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK002: A phase 2 clinical study evaluating haplo-identical NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center. The phase 2 trial for K-NK002 will be conducted in collaboration with the Bone Marrow Transplant Clinical ...
Manufactured by:AGC Biologics based inBothell, WASHINGTON (USA)
AGC Biologics develops and manufactures diverse cell therapies including CD34+ hematopoietic stem cells, autologous and allogenic T-cells, and NK cells. Our cell therapy capabilities cover numerous technologies, ranging from closed to open systems at different scales, depending on client needs. Our quality systems, facility layout and regulatory qualifications enable us to serve both ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Probody therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are designed to take advantage of high levels of protease activity in the tumor microenvironment. Their target-binding regions are masked to limit activity ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
An allogenic NK cell therapy that targets tumors expressing mHsp70. Patients are selected with high mHsp70 exosomes in their blood using our Companion Diagnostic AP-CDx (described below). We obtain PBMCs from healthy donors by apheresis, their NK cells are expanded, and incubated ex vivo with TKD and IL-2, followed by freezing, thawing and intravenous administration to ...
Manufactured by:Nkarta, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Cell therapy, a new approach that uses immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. First generation approaches have focused on T-cells, which have shown great promise in hematologic malignancies but are plagued with unwanted side effects and, to date, have not shown similar activity in solid tumors. Nkarta was founded to address these ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
CYNK-001 is the only cryopreserved, allogeneic, off-the-shelf, natural killer (NK) cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers, solid tumors, and infectious disease. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive ...
Manufactured by:Bio-Techne based inMinneapolis, MINNESOTA (USA)
Immune cell therapy is rapidly emerging as an important alternative for cancer treatment, as well as treatment of autoimmune disease. Also known as adoptive cell therapy or cellular immunotherapy, it supercharges an individual’s immune cells to fight disease. ...